Traws Pharma, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Traws Pharma reported a significant increase in R&D expenses for Q1 2026, alongside a continued net loss and concerns about its ability to continue as a going concern.
NASDAQ
Traws Pharma reports a net income for the nine months ended September 30, 2025, but faces substantial doubt about its ability to continue as a going concern due to limited cash reserves.
NASDAQ
Traws Pharma, a clinical-stage biopharmaceutical company, reported a net income of $20.6 million for the first half of 2025, driven by warrant revaluation and deferred revenue recognition, despite ongoing operating losses and a going concern warning.
NASDAQ
10-Q: Traws Pharma Reports Q1 2025 Results, Cites Going Concern Uncertainty Despite Net Income Boost
Traws Pharma reports a net income of $21.49 million for Q1 2025, primarily driven by changes in warrant liability, but expresses substantial doubt about its ability to continue as a going concern due to insufficient cash.
NASDAQ
Traws Pharma's Q3 2024 results reveal a significant net loss driven by a large in-process R&D expense, alongside ongoing concerns about the company's ability to continue as a going concern.
NASDAQ
10-Q: Traws Pharma Reports Second Quarter 2024 Results Following Merger, Faces Going Concern Uncertainty
Traws Pharma reports a significant net loss for the second quarter of 2024, driven by a large in-process R&D expense related to the acquisition of Trawsfynydd Therapeutics, and expresses substantial doubt about its ability to continue as a going concern.
NASDAQ
Traws Pharma, formerly Onconova Therapeutics, reports a net loss of $4.983 million for the first quarter of 2024, alongside a strategic merger and pipeline expansion.